Physician profile
Daniel C Burnes
NPI 1487851077
$1,738.61
in general payments reported to CMS, 2019-2025
21 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $317 · 2021: $152 · 2022: $101 · 2023: $89.20 · 2024: $428 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $834 · Entertainment: $13.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $834.45 |
| Entertainment | $13.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $481.54 | 2019-2025 | Relistor, Trulance |
| Indivior INC. | $302.52 | 2019-2025 | Sublocade |
| Pfizer INC. | $272.77 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $216.72 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $70.78 | 2019-2021 | |
| Antares Pharma, INC. | $66.21 | 2019-2022 | |
| Exact Sciences Corporation | $56.31 | 2024-2025 | Cologuard Collection Kit |
| Tolmar, INC. | $30.74 | 2025 | Jatenzo |
| Glaxosmithkline, LLC. | $26.61 | 2021 | |
| Novo Nordisk INC | $22.50 | 2024 | Rybelsus |
| Vapotherm INC | $21.28 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.23 | 2025 | Caplyta |
| Protega Pharmaceutials INC | $20.77 | 2025 | Roxybond |
| Lilly USA, LLC | $20.28 | 2024 | Mounjaro |
| Almatica Pharma LLC | $17.32 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $17.15 | 2023 | Sunosi |
| Scilex Pharmaceuticals INC. | $16.34 | 2021 | |
| Virtus Pharmaceuticals LLC | $16.06 | 2023 | Levorphanol Tartrate |
| Orexo US, INC. | $15.25 | 2021 | |
| Optos, INC. | $13.78 | 2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Gilead Sciences, INC. | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Burnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.